Insight Inv LLC Has $210,000 Stock Position in Pfizer Inc. $PFE

Insight Inv LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 55.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 8,651 shares of the biopharmaceutical company’s stock after selling 10,688 shares during the period. Insight Inv LLC’s holdings in Pfizer were worth $210,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Armstrong Fleming & Moore Inc bought a new position in shares of Pfizer during the second quarter valued at $239,000. Tectonic Advisors LLC raised its stake in shares of Pfizer by 22.1% during the second quarter. Tectonic Advisors LLC now owns 298,687 shares of the biopharmaceutical company’s stock valued at $7,240,000 after acquiring an additional 54,068 shares during the last quarter. Cohen Investment Advisors LLC raised its stake in shares of Pfizer by 16.9% during the second quarter. Cohen Investment Advisors LLC now owns 103,490 shares of the biopharmaceutical company’s stock valued at $2,509,000 after acquiring an additional 14,984 shares during the last quarter. Vontobel Holding Ltd. raised its stake in shares of Pfizer by 2.1% during the second quarter. Vontobel Holding Ltd. now owns 736,235 shares of the biopharmaceutical company’s stock valued at $17,846,000 after acquiring an additional 14,808 shares during the last quarter. Finally, Maryland State Retirement & Pension System raised its stake in shares of Pfizer by 4.1% during the second quarter. Maryland State Retirement & Pension System now owns 276,125 shares of the biopharmaceutical company’s stock valued at $6,693,000 after acquiring an additional 10,986 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 2.3%

NYSE:PFE opened at $25.67 on Thursday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $145.95 billion, a price-to-earnings ratio of 13.65, a PEG ratio of 0.86 and a beta of 0.55. The firm has a fifty day simple moving average of $24.79 and a two-hundred day simple moving average of $24.15. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

PFE has been the subject of several analyst reports. Bank of America raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday. UBS Group reissued a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Citigroup lifted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.